Bright Green To Supply DEA-Approved Cannabis Extracts And Psychedelics To FDA-Registered Pharmaceutical Company
Bright Green To Supply DEA-Approved Cannabis Extracts And Psychedelics To FDA-Registered Pharmaceutical Company
Bright Green Corporation (NASDAQ:BGXX) has signed a letter of intent (LOI) to supply its DEA-approved cannabis extracts and plant-based psychedelics to Benuvia Operations, an FDA-registered, DEA-licensed and cGMP-certified leader in pharmaceutical cannabinoids and psychedelic compounds currently under investigation for clinical use.
Bright Green Corporation（納斯達克：BGXX）已簽署意向書（LOI），供應其獲得美國藥物執照認可的大麻提取物和基於植物的致幻劑給Benuvia Operations，這是一家FDA註冊、DEA許可並且cGMP認證的藥品類和致幻劑公司，目前正在接受臨床研究。
In February, the Grants, New Mexico-based company received final approval from the New Mexico Board of Pharmacy and the DEA to register, license and authorize Schedule I and Schedule II plant-based substances and active pharmaceutical ingredients for research, production and manufacturing purposes.
今年二月，總部位於新墨西哥的公司獲得了新墨西哥州藥房委員會和DEA的最終批准，註冊，許可並授權計劃I和計劃II植物成分和活性藥用成分用於研究、生產和製造目的。
Under the proposed supply agreement in the LOI, Benuvia plans to utilize Bright Green's unique capability to produce Schedule I and II raw materials, fully compliant with Good Agricultural and Collection Practices (GACP), Good Manufacturing Practices (GMP) and DEA regulations. These raw materials will be used to manufacture cGMP pharmaceutical-grade Active Pharmaceutical Ingredients domestically for both U.S. and global markets.
根據意向書中提議的供應協議，Benuvia計劃利用Bright Green獨特的能力生產符合良好農業和收集規範（GACP），良好製造規範（GMP）和DEA規定的計劃I和計劃II原材料。這些原材料將用於在美國和全球市場上生產符合cGMP標準的活性藥用成分。
Read Also: LSD's Potential In Pain Management: New Research Sheds Light On Psychedelic's Influence On Brain Networks
閱讀更多：LSD在疼痛管理中的潛力：新研究揭示致幻劑對大腦網絡的影響
Schedule I substances include cannabis, psilocybin, mescaline, peyote and ibogaine. Schedule II substances include various forms of opium, such as raw opium, poppy straw, opium extracts, powdered opium, granulated opium, opium tincture, opium fluid extracts and opium straw concentrates, as well as erythroxylon coca (cocaine).
計劃I物質包括大麻、牛津小蘑菇、麥角胺、佩約特和伊若巴胺。計劃II物質包括各種形式的鴉片，如生鴉片、罌粟稈、鴉片提取物、鴉片粉、顆粒狀鴉片、鴉片浸劑、鴉片液體提取物和鴉片秸稈濃縮物，以及古柯毒鹼。
- Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
- 獲取Benzinga獨家分析和大麻行業及市場的頭條新聞，每天免費發送到您的收件箱。請在這裏訂閱我們的新聞通訊。如果您對業務真誠地感興趣，就不能錯過這些。
Bright Green sees this as yet another step towards becoming the leading domestic supplier of DEA-controlled, plant-based raw materials to produce cannabinoid, psychedelic and opioid-based drugs in the USA. With a new round of fundraising and supply agreements in the works, the company says it is positioned for a strong performance in 2025.
Bright Green視這一舉措爲躍升爲美國領先的DEA管制植物成分原料供應商邁出的又一步。隨着一輪新的籌資和供應協議正在進行中，該公司表示已爲2025年的強勁表現做好了準備。
The Drug Enforcement Administration (DEA) just completed its annual operational procedures for all Schedule I and II drug cultivation and manufacturing in July. Bright Green met this national standard and is now one step closer to beginning operations and supplying the pharmaceutical world with the materials it needs to innovate.
美國禁毒局（DEA）剛剛在7月份完成了其針對I類和II類藥物種植和製造的年度運營程序。全綠公司達到了這一國家標準，現在離開始運營並向藥品界提供創新所需的材料又近了一步。
Price Action
股價變動
Bright Green Corporation shares traded 2.6% higher at $0.23 per share at the time of publication.
Bright Green Corporation股票交易價每股上漲2.6%，達到0.23美元。
- Village Farms And TILT Holdings: A Tale Of Two Cannabis Companies Facing Diverging Fortunes
- Village Farms和TILt Holdings：兩家大麻公司面臨截然不同的命運
Photo: Courtesy of Ryland zweifel via Shutterstock
照片：由Ryland zweifel通過Shutterstock提供的禮物